Citations 1
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)
Chabrun, Floris , Schwartz, Daniel L. , Gentile, Susanna, Elias, K. , Gupta, Tulika , Perry, Jacqueline , Santos, David M. Cordas dos , Hielscher, Thomas , Werly, Annika, Schmidt, Sophia, Liacos, Christine‐Ivy , Kanellias, Nikolaos , Gisbert, Noelia Collado, Chavda, Selina J , Ainley, Louise , Magistris, Claudio De, Pettine, Loredana , Timonian, Michael , Tobia, Catherine, Phan, Sally, Lamb, Jennifer, Silverio, Maria-Theresa, O’Donnell, Elizabeth , Mateos, María‐Victoria , Kumar, Shaji , Kastritis, Efstathis, Trippa, Lorenzo , Mai, Elias K , Santos, David Cordas Dos , Timonian, Michael , Alberge, Jean-Baptiste , Bolli, Niccolo' , Yong, Kwee , Kortüm, Martin , Einsele, Hermann , Mateos, María-Victoria , Kumar, Shaji K , San-Miguel, Jesus , Paiva, Bruno , Dimopoulos, Meletios A , Raab, Marc S , Ghobrial, Irene M , Schwartz, Daniel S. , Gentile, Susanna , Gupta, Tulika R. , Perry, Jacqueline, Schmidt, Sophia K., Theodorakakou, Foteini , Fotiou, Despina , Liacos, Christine Ivy, Martín‐Sánchez, Esperanza , Termini, Rosalinda , Waldschmidt, Johannes M , Ainley, Louise, Vià, Matteo Da , Alberge, Jean-Baptiste , Patel, Vidhi, Costello, Patrick , Tobia, Catherine, Phan, Sally, Lamb, Jennifer, Silverio, Maria-Theresa, Davis, Maya, Marinac, Catherine R. , Nadeem, Omar , Bolli, Niccolò , Yong, Kwee , Kortüm, K. Martin , Miguel, Jesús F. San , Paiva, Bruno , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Raab, Marc S. , Ghobrial, Irene M.
No container title available | June 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract Accurate prediction of risk of progression from smoldering (SMM) to active multiple myeloma (MM) is paramount to individualized early therapeutic strategies with minimum risk of overtreatment. Current risk stratification models do not account for evolving biomarker trajectories. We assembled the largest cohort to date of 2,270 SMM patients from six international centers with longitudinal clinical and biological data to train and validate the PANGEA 2.0 risk models. Four evolving biomarkers were significantly associated with shorter time-to-progression: M-protein increase ≥0.2g/dL, involved:uninvolved serum free light chain ratio increase ≥20, creatinine increase >25%, and hemoglobin decrease ≥1.5g/dL. PANGEA 2.0 outperforms established models including the 20/2/20 and IMWG models by more accurately predicting progression (C-statistics=0.69–0.84), even without biomarker history (C-statistics=0.69–0.83) or recent bone marrow biopsy. PANGEA 2.0 is an easy-to-use, open-access tool (https://ghobrial.shinyapps.io/pangea_2_calculator) to improve and individualize SMM risk stratification. Validation tools are available to compare PANGEA 2.0 to established models (https://ghobrial.shinyapps.io/pangea_validation).